Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection

Suggested Citation

Shein A.M.S., Wannigama D.L., Hurst C., Monk P.N., Amarasiri M., Badavath V.N., Phattharapornjaroen P., Ditcham W.G.F., Ounjai P., Saethang T., Chantaravisoot N., Thuptimdang W., Luk-in S., Nilgate S., Rirerm U., Tanasatitchai C., Kueakulpattana N., Laowansiri M., Liao T., Kupwiwat R., Rojanathanes R., Ngamwongsatit N., Thammahong A., Ishikawa H., Pletzer D., Leelahavanichkul A., Ragupathi N.K.D., Wapeesittipan P., Ali Hosseini Rad S.M., Kanjanabuch T., Storer R.J., Miyanaga K., Cui L., Hamamoto H., Higgins P.G., Kicic A., Chatsuwan T., Hongsing P., Abe S. Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection. Biomedicine and Pharmacotherapy Vol.168 (2023). doi:10.1016/j.biopha.2023.115793 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/90925

Availability

Collections